Oscar Health Inc. (OSCR) Misses Q2 EPS by 5c
Oscar Health Inc. (NYSE: OSCR) reported Q2 EPS of ($0.53), $0.05 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.1 billion.
Full Year 2022 Outlook: | ||||||||
|
| Low |
| High | ||||
Direct and Assumed Policy Premiums (in thousands) |
| $ | 6,100,000 |
|
| $ | 6,400,000 |
|
Medical Loss Ratio |
|
| 84 | % |
|
| 86 | % |
InsuranceCo Administrative Expense Ratio |
|
| 19.5 | % |
|
| 20.5 | % |
InsuranceCo Combined Ratio |
|
| 104 | % |
|
| 106 | % |
Adjusted Administrative Expense Ratio |
|
| 24 | % |
|
| 26 | % |
Adjusted EBITDA(1) (in thousands) |
| $ | (480,000 | ) |
| $ | (380,000 | ) |
(1) | Oscar has not provided a quantitative reconciliation of forecasted Adjusted EBITDA to forecasted GAAP net loss within this press release because Oscar is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, stock-based compensation expense. These items, which could materially affect the computation of forecasted GAAP net loss, are inherently uncertain and depend on various factors, some of which are outside of Oscar’s control. As such, any associated estimate and its impact on GAAP net loss could vary materially. For more information regarding Adjusted EBITDA, please see “Key Operating and Non-GAAP Metrics” below. |
The foregoing statements represent management's current estimates as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.